Company Description
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States.
The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications.
Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 2013 |
| IPO Date | Mar 24, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Gabriele Marco Cerrone |
Contact Details
Address: 14/15 Conduit Street London, W1S 2XJ United Kingdom | |
| Website | tizianalifesciences.com |
Stock Details
| Ticker Symbol | TLSA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001723069 |
| CUSIP Number | 88875G101 |
| ISIN Number | BMG889121031 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ivor R. Elrifi Ph.D. | Chief Executive Officer and Executive Director |
| Gabriele Marco Antonio Cerrone M.B.A. | Founder, Executive Chairman and Interim Chief Executive Officer |
| Keeren Shah | Chief Operating Officer and Chief Financial Officer |
| Dr. William A. Clementi Ph.D., Pharm.D. | Chief Development Officer |
| Dr. Napoleone Ferrara M.D. | Member of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 17, 2024 | 6-K | Report of foreign issuer |
| Dec 4, 2024 | 6-K | Report of foreign issuer |
| Nov 19, 2024 | 6-K | Report of foreign issuer |
| Nov 1, 2024 | 6-K | Report of foreign issuer |
| Nov 1, 2024 | 424B5 | Filing |
| Nov 1, 2024 | 6-K | Report of foreign issuer |
| Oct 30, 2024 | 6-K | Report of foreign issuer |
| Oct 25, 2024 | 6-K | Report of foreign issuer |
| Oct 25, 2024 | 424B5 | Filing |
| Oct 18, 2024 | 6-K | Report of foreign issuer |